A candidate probiotic with unfavourable effects in subjects with irritable bowel syndrome: A randomised contr olled trial

BMC Gastroenterology

Volumn 10, Issue , 2010, Pages

  Ligaarden, Solveig C ^a,b   Axelsson, Lars ^c   Naterstad, Kristine ^c   Lydersen, Stian ^b   Farup, Per G ^a,b  

^a INNLANDET HOSPITAL TRUST   (Norway)

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^c NOFIMA   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; PROBIOTIC AGENT;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COLONY FORMING UNIT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG TREATMENT FAILURE; FEMALE; HUMAN; IRRITABLE COLON; LACTOBACILLUS PLANTARUM; MALE; NONHUMAN; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; SYMPTOM; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; ABDOMINAL PAIN; CONSTIPATION; DIARRHEA; DIET THERAPY; FECES; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; PATHOGENICITY; PATIENT SATISFACTION; SPECIES DIFFERENCE;

ABDOMINAL PAIN; ADULT; AGED; CONSTIPATION; DIARRHEA; FECES; FEMALE; HUMANS; IRRITABLE BOWEL SYNDROME; LACTOBACILLUS PLANTARUM; MALE; MIDDLE AGED; PATIENT SATISFACTION; PROBIOTICS; SPECIES SPECIFICITY;

EID: 77951895205     PISSN: None     EISSN: 1471230X     Source Type: Journal    
DOI: 10.1186/1471-230X-10-16     Document Type: Article

References (26)

1. Spiller R, Aziz Q, Creed F, Emmanuel A, Houghton L, Hungin P, Jones R, Kumar D, Rubin G, Trudgill N, Whorwell P. Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut 2007, 56:1770-1798. 10.1136/gut.2007.119446, 17488783.
2. Chang L. Review article: epidemiology and quality of life in functional gastrointestinal disorders. Aliment Pharmacol Ther 2004, 20(Suppl 7):31-39. 10.1111/j.1365-2036.2004.02183.x, 15521853.
3. Drossman DA. Review article: an integrated approach to the irritable bowel syndrome. Aliment Pharmacol Ther 1999, 13(Suppl 2):3-14. 10.1046/j.1365-2036.1999.0130s2003.x, 10429736.
4. Zoetendal EG, Vaughan EE, de Vos WM. A microbial world within us. Mol Microbiol 2006, 59:1639-1650. 10.1111/j.1365-2958.2006.05056.x, 16553872.
5. FAO/WHO Expert Consultation Group Health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria 2001, Argentina: FAO/WHO, FAO/WHO Expert Consultation Group.
6. Spiller R. Review article: probiotics and prebiotics in irritable bowel syndrome. Aliment Pharmacol Ther 2008, 28:385-396. 10.1111/j.1365-2036.2008.03750.x, 18532993.
7. Nobaek S, Johansson ML, Molin G, Ahrne S, Jeppsson B. Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenterol 2000, 95:1231-1238. 10.1111/j.1572-0241.2000.02015.x, 10811333.
8. Klingberg TD, Pedersen MH, Cencic A, Budde BB. Application of measurements of transepithelial electrical resistance of intestinal epithelial cell monolayers to evaluate probiotic activity. Appl Environ Microbiol 2005, 71:7528-7530. 10.1128/AEM.71.11.7528-7530.2005, 1287686, 16269795.
9. Klingberg TD, Axelsson L, Naterstad K, Elsser D, Budde BB. Identification of potential probiotic starter cultures for Scandinavian-type fermented sausages. Int J Food Microbiol 2005, 105:419-431. 10.1016/j.ijfoodmicro.2005.03.020, 16076509.
10. Klingberg TD, Budde BB. The survival and persistence in the human gastrointestinal tract of five potential probiotic lactobacilli consumed as freeze-dried cultures or as probiotic sausage. Int J Food Microbiol 2006, 109:157-159. 10.1016/j.ijfoodmicro.2006.01.014, 16504324.
11. Heaton KW. Dietary fibre. BMJ 1990, 300:1479-1480. 10.1136/bmj.300.6738.1479, 1663183, 2164853.
12. Walter SD. Number needed to treat (NNT): estimation of a measure of clinical benefit. Stat Med 2001, 20:3947-3962. 10.1002/sim.1173, 11782045.
13. Quigley EM. The efficacy of probiotics in IBS. J Clin Gastroenterol 2008, 42(Suppl 2):S85-S90. 10.1097/MCG.0b013e31816244ca, 18542036.
14. Guyonnet D, Chassany O, Ducrotte P, Picard C, Mouret M, Mercier CH, Matuchansky C. Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial. Aliment Pharmacol Ther 2007, 26:475-486.
15. O'Mahony L, McCarthy J, Kelly P, Hurley G, Luo F, Chen K, O'Sullivan GC, Kiely B, Collins JK, Shanahan F, Quigley EM. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005, 128:541-551. 10.1053/j.gastro.2004.11.050, 15765388.
16. Whorwell PJ, Altringer L, Morel J, Bond Y, Charbonneau D, O'Mahony L, Kiely B, Shanahan F, Quigley EMM. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol 2006, 101:1581-1590. 10.1111/j.1572-0241.2006.00734.x, 16863564.
17. O'Sullivan MA, O'Morain CA. Bacterial supplementation in the irritable bowel syndrome. A randomised double-blind placebo-controlled crossover study. Dig Liver Dis 2000, 32:294-301. 10.1016/S1590-8658(00)80021-3, 11515626.
18. Kajander K, Myllyluoma E, Rajilic-Stojanovic M, Kyronpalo S, Rasmussen M, Jarvenpaa S, Zoetendal EG, de Vos WM, Vapaatalo H, Korpela R. Clinical trial: multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota. Aliment Pharmacol Ther 2008, 27:48-57.
19. Sen S, Mullan MM, Parker TJ, Woolner JT, Tarry SA, Hunter JO. Effect of Lactobacillus plantarum 299v on colonic fermentation and symptoms of irritable bowel syndrome. Dig Dis Sci 2002, 47:2615-2260. 10.1023/A:1020597001460, 12452404.
20. Montrose DC, Floch MH. Probiotics used in human studies. J Clin Gastroenterol 2005, 39:469-484. 10.1097/01.mcg.0000165649.32371.71, 15942432.
21. Boyle RJ, Robins-Browne RM, Tang MLK. Probiotic use in clinical practice: what are the risks?. Am J Clin Nutr 2006, 83:1256-1264.
22. Besselink MG, van Santvoort HC, Buskens E, Boermeester MA, van Goor H, Timmerman HM, Nieuwenhuijs VB, Bollen TL, van Ramshorst B, Witteman BJ, Rosman C, Ploeg RJ, Boermeester MA, Schaapherder AF, Dejong CH, Wahab PJ, van Laarhoven CJ, Harst E, van Eijck CH, Cuesta MA, Akkermans LM, Gooszen HG. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet 2008, 371:651-659. 10.1016/S0140-6736(08)60207-X, 18279948.
23. Niedzielin K, Kordecki H, Birkenfeld B. A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome. Eur J Gastroenterol Hepatol 2001, 13:1143-1147. 10.1097/00042737-200110000-00004, 11711768.
24. Niv E, Naftali T, Hallak R, Vaisman N. The efficacy of Lactobacillus reuteri ATCC 55730 in the treatment of patients with irritable bowel syndrome-a double blind, placebo-controlled, randomized study. Clin Nutr 2005, 24:925-931. 10.1016/j.clnu.2005.06.001, 16051399.
25. Ersryd A, Posserud I, Abrahamsson H, Simren M. Subtyping the irritable bowel syndrome by predominant bowel habit: Rome II versus Rome III. Aliment Pharmacol Ther 2007, 26:953-961.
26. Woods JR, Williams JG, Tavel M. The two-period crossover design in medical research. Ann Intern Med 1989, 110:560-566.